Magali Taiel, Chief Medical Officer, will present the company during the virtual Ophthalmology Futures Retina Forum as well as the latest clinical results from its lead gene therapy treatment LUMEVOQ® (GS010) to treat LHON, which has been submitted for marketing approval in Europe in September 2020.

  • Session: Company Presentations 2
  • Time: 5.30 – 6.30 PM CEST (Local Time)